A detailed history of Advisor Group Holdings, Inc. transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 5,267 shares of PDSB stock, worth $11,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,267
Previous 5,267 -0.0%
Holding current value
$11,850
Previous $15,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.55 - $4.02 $43 - $68
17 Added 0.32%
5,267 $15,000
Q1 2024

May 10, 2024

BUY
$3.85 - $6.59 $19,250 - $32,950
5,000 Added 2000.0%
5,250 $20,000
Q4 2023

Feb 12, 2024

SELL
$3.95 - $6.58 $23,700 - $39,480
-6,000 Reduced 96.0%
250 $1,000
Q3 2023

Nov 13, 2023

BUY
$4.8 - $6.4 $20,400 - $27,200
4,250 Added 212.5%
6,250 $31,000
Q2 2023

Aug 10, 2023

SELL
$5.03 - $9.9 $2,515 - $4,950
-500 Reduced 20.0%
2,000 $10,000
Q1 2023

May 12, 2023

BUY
$5.68 - $11.99 $8,508 - $17,961
1,498 Added 149.5%
2,500 $15,000
Q4 2022

Feb 10, 2023

BUY
$3.28 - $13.2 $6 - $26
2 Added 0.2%
1,002 $13,000
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.79 $32 - $63
-11 Reduced 1.09%
1,000 $3,000
Q2 2022

Aug 10, 2022

SELL
$3.05 - $6.68 $366 - $801
-120 Reduced 10.61%
1,011 $4,000
Q1 2022

May 04, 2022

SELL
$4.78 - $8.43 $2,390 - $4,215
-500 Reduced 30.66%
1,131 $7,000
Q3 2021

Nov 05, 2021

SELL
$9.33 - $17.08 $8,210 - $15,030
-880 Reduced 35.05%
1,631 $25,000
Q2 2021

Aug 02, 2021

BUY
$4.35 - $12.86 $4,350 - $12,860
1,000 Added 66.18%
2,511 $32,000
Q1 2021

May 13, 2021

BUY
$2.28 - $6.81 $1,595 - $4,767
700 Added 86.31%
1,511 $7,000
Q3 2020

Nov 12, 2020

BUY
$1.67 - $4.67 $1,336 - $3,736
800 Added 7272.73%
811 $2,000
Q1 2020

May 18, 2020

BUY
$0.67 - $3.04 $7 - $33
11 New
11 $0

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $64M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.